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ABSTRACT
REGULATION OF ANTI-ANGIOGENIC PEDF THROUGH A TSP-1 – CD36
PATHWAY IN PROSTATE CANCER
by
Ayesha Chawla
The University of Wisconsin-Milwaukee, 2013
Under the Supervision of Jennifer A. Doll, PhD

Prostate cancer (PCa) is the most common type of cancer diagnosed in American
men. Cancer progression is associated with increased angiogenesis, and
thrombospondin-1 (TSP‐1) and pigment epithelium derived factor (PEDF), both
potent anti-angiogenic molecules, are downregulated in PCa cells. TSP-1 exerts its
activity through binding to several cell surface receptors such as CD36. Both TSP-1
and PEDF are multi-functional proteins and have been linked to lipid metabolism in
other cell types. Moreover, TSP-1 – PEDF regulatory loops have been identified in
some cell types. PEDF has been shown to inhibit PCa growth through its effects on
angiogenesis and directly on the PCa cells; however, how PEDF expression levels
are regulated in prostate cells is currently unknown. Here, we hypothesized that
TSP-1 may regulate PEDF expression and lipid metabolism in PCa cells.
I collected and examined PEDF levels in both cell lysate and serum-free
conditioned media samples from TSP-1 and anti-CD36 antibody treated prostate
cells and examined PEDF levels. Both TSP-1 and anti-CD36 treatment increased
PEDF expression in normal prostate epithelial cells, RWPE-1, and in PCa cells, PC3 and LNCaP. The expression of candidate TSP-1 – CD36 signaling mediators, fyn,
p38 MAPK and JNK, were also examined in treated samples. I found that TSP-1
treatment elevated expression of fyn, p38 and JNK in PC-3 and DU145 cells. In
ii

contrast, blocking the CD36 receptor diminished the expression of each signaling
mediator.
My results are the first to show that a regulatory loop exists between TSP-1 and
PEDF in prostate cells. The observation that treatment with anti-CD36 antibody also
increased PEDF suggests that TSP-1 regulation of PEDF may be mediated through
the CD36 receptor. These observations suggest that one mechanism of PEDF downregulation in PCa cells may be due to loss of TSP-1 expression. Moreover, this
pathway could be exploited for novel therapeutic interventions.
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INTRODUCTION
Prostate cancer
Prostate cancer (PCa) is the most commonly diagnosed type of cancer and the
second leading cause of death in men in the United States [1]. As estimated by the
National Cancer Institute at the National Institutes of Health, there will be 238,590
new cases and 29,720 deaths due to prostate cancer in 2013 [1]. It is estimated that
by the age of 80, approximately 80% of men will have some cancerous cells in their
prostate [2]. PCa screening is performed by measuring the serum prostate specific
antigen (PSA) in the blood in conjunction with a digital rectal examination (DRE). If
these tests indicate that PCa may be present, a transrectal ultrasound (TRUS)
guided needle biopsy is taken for histologic examination for a definitive diagnostics.
Prostate carcinomas are assigned a Gleason score to indicate histological grade.
The Gleason grading system is the dominant grading system used for prostate
carcinomas worldwide [3]. It is based on the histology of the carcinoma cells of the
prostate. A Gleason score ranges from 2-10, with scores over 7 considered high
grade patterns.
While these approaches have led to increased diagnosis of cancer in men
who may not have a clinically significant disease [4], the chance of cancer-specific
survival is improved for intermediate and high risk cancers [5]. There are several
treatment options for PCa including androgen deprivation therapy, surgical removal
of the prostate and radiation therapy [6]. Androgen deprivation therapy is often the
first line of treatment for metastatic cancers; however, most men eventually progress
to hormone refractory disease. Chemotherapy can provide a survival benefit for
some men with hormone refractory, metastatic disease; however, new treatments
are needed.
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Prostate cancer, diet and obesity
Despite much work, the causes of PCa have not yet been well elucidated, although
some risk factors, such as age, race, genetic allelic variants, and family history have
been identified [7]. Globally, the incidence and mortality of prostate cancer vary
widely [1]. Diet is associated with prostate cancer risk and mortality as established in
epidemiological studies [7]. It has been reported that diet may have a greater impact
on the aggressive form of disease as compared to the indolent form of PCa [8].
Epidemiological studies suggests that lycopene, from cooked tomatoes, may be
protective against developing PCa; however, these data have not been entirely
consistent (as reviewed in [9]). Epidemiological data suggests that there is a high
correlation between PCa risk and dietary fat derived from meat (as reviewed in [9]).
Consumption of red meat, particularly, has been consistently linked to development
of more aggressive disease [10-14]. While, there is no correlation between obesity
and PCa risk [8], studies have suggested that obese men are diagnosed more often
with more advanced and high grade cancer [8]. Obese men are also more likely to
die of PCa than lean men [8, 15]. Serum androgen levels and other potential PCa
growth factors have been shown to be influenced by body mass. Thus, while obesity
is not associated with increased PCa risk, it makes the disease worse. However, the
association between the two, as established by epidemiological studies, has been
inconsistent [16-20].

Role of angiogenesis inhibitors in PCa
Like most solid tumors, the growth of PCa beyond a few millimeters in diameter is
dependent on induction of angiogenesis, the growth of new vessels from existing
vessels [21]. Complex interactions between vascular growth factors, including both
positive and negative factors, regulate the growth of new blood vessels [22-24].
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There is a fine balance between high levels of inhibitors and low levels of inducers in
most normal tissues [25, 26]. However, when inducer secretion predominates, the
endothelial cells in the adjacent vessels are stimulated to proliferate and migrate
toward the source tissue [27]. The increase of inducers or decrease in the secretion
of inhibitors or a combination of both occurs as result of genetic or epigenetic
alterations in cancers [25, 28]. Decreased expression of several angiogenic inhibitors
occurs in PCa, including decreased expression of thrombospondin-1 (TSP-1) and
pigment epithelium derived factor (PEDF) [29, 30]. Both of these proteins have
multiple, cell type specific functions.

PEDF in PCa
Pigment epithelium derived factor (PEDF) is a 50kDa secreted glycoprotein that
belongs to the serpin (serine protease inhibitors) group [31]. PEDF was first
discovered as a differentiation factor for retinoblastoma cells [32, 33]. It was isolated
from the conditioned media of the retinal pigment epithelial cells. PEDF levels are
known to decline with age and it serves as a marker for young cells [34, 35].
PEDF is a potent inhibitor of both physiological and pathological angiogenesis
[36]. Downregulation of PEDF has been observed in many cancer types, such as
melanoma, cervical cancer and PCa [37-39]. Also, the decreased expression of
PEDF has been associated with poor prognosis and increased metastasis in the
prostate [30]. It has been reported that re-expression of the PEDF gene in human
hormone refractory PCa PC-3 cells is associated with decreased tumor growth [40].
Recently, Hirsch et al. showed that PEDF suppresses IL-8 production in PCa cells
[41]. IL-8 has been shown to be involved in PCa progression. In mice, loss of PEDF
expression is associated with the development of prostatic epithelial cell hyperplasia
and increased stromal vascularization in the prostate [30].
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PEDF is also secreted by adipocyte and is involved with insulin resistance in
the body [42, 43]. It has been shown to have a profound effect on lipid metabolism.
Studies have shown that PEDF influences systemic fatty acid metabolism by
promoting lipolysis in an adipocyte triglyceride lipase dependent manner [44].
However, whether PEDF, lipid metabolism and PCa are linked remains to be
explored.

TSP-1 in PCa
Thrombospondins are a family of five multidomain, calcium binding extracellular
glycoproteins. They are synthesized and secreted in a wide variety of cells [45].
Amongst all the members of the thrombospondin family (TSP-1, TSP-2, TSP-3 TSP4 and TSP-5), TSP-1 has been studied most widely. It was the first naturally
occurring inhibitor of angiogenesis to be identified [46]. TSP-1 is a large (450kDa)
trimeric molecule that binds to several receptors and ligands. It serves as a prototype
member of the family [46, 47]. TSP-1 was first discovered in activated platelets [48].
A variety of functions are associated with the TSP-1 molecule. It stimulates matrix
assembly by binding to matrix proteins such as collagen and fibronectin and also
regulates matrix digestion by metalloproteinases and plasmin. TSP-1 has been
shown to stimulate apoptosis of the endothelial cells and T cells; however, it
promotes survival of the vascular smooth muscle cells [49, 50]. Fibroblasts, smooth
muscle cells, adipocytes and macrophages are amongst a few cells that secrete
TSP-1 [51, 52]. TSP-1 is a major activator of transforming growth factor- (TGF-)
and also activates neutrophils [53-55]. In the prostate, activation of TGF-β by TSP-1
plays a crucial role in regulating prostate growth [56]. The expression of TSP-1 is
regulated by the tumor suppressor p53 in prostate tissue [57]. One of the ways by
which TSP-1 inhibits angiogenesis is that it causes apoptosis in macrophages,
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eventually reducing inflammation and attenuating cytokines responsible for
angiogenesis [58].
Tumor progression is a multistep process wherein the cells acquire (1) the
ability to evade apoptosis, (2) insensitivity to antigrowth signals, (3) self-sufficiency in
growth signals, (4) limitless replicative potential, (5) sustained angiogenesis and (6)
the ability to invade and metastasize [59]. TSP-1 is important in regulating
angiogenesis. The expression of TSP-1 is decreased in many cancer types,
including prostate, pancreas and urothelial cancer [29, 60, 61]. A decrease in TSP-1
expression in prostate carcinoma cells has been associated with mutant p53 [57].
Naturally occurring angiogenesis inducers, such as vascular endothelial growth
factor (VEGF) and fibroblast growth factor (FGF-2), are increased in PCa tissues
[29]. This promotes tumor progression as a result of sustained angiogenesis. In
PCa, TSP-1 has been thought to suppress angiogenesis by creating a matrix barrier
between tumor and stroma [62]. Tissue levels of TSP-1 have been found to increase
following castration in rat model [63] and in persons undergoing androgendeprivation therapy [56]. The TSP-1 knockout phenotype has been established to
have many phenotypes, including hyperplasia in the prostate [53].

TSP-1 and CD36
TSP-1 binds to several cellular receptors, such as CD36, CD47 and several integrins
[64]. CD36 is a single chain, 88 kDa, highly glycosylated protein that is a multi-ligand
scavenger receptor involved in fatty acid and lipid metabolism [65]. Amongst the
many CD36 functions, it is a transporter of long chain fatty acids and therefore, is
also called fatty acid translocase [66]. CD36 is involved in fat and fat soluble vitamin
absorption in the liver [67]. In endothelial cells, one study showed that TSP-1
mediated its anti-angiogenic activity through CD36 binding and induction of apoptotic
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signals [68]. While CD36 is expressed in the normal prostate and in PCa [69], the
interaction between TSP-1 and CD36 in prostate cells has not been studied.

TSP-1 and signaling pathways
In endothelial cells, the anti-angiogenic activity of TSP-1, upon binding with the
CD36 receptor is mediated through intracellular signaling molecules [68]. Upon TSP1 binding with the CD36 receptor, a signaling cascade is initiated. This signaling
pathway in endothelial cells involves the non-receptor protein tyrosine kinase Fyn,
the mitogen activated protein kinases (MAPKs) p38 and c-Jun N- terminal kinase
(JNK), and caspase-3 [68]. It is believed that the CD36 receptor itself does not have
any kinase activity and that its oligomers most likely utilize adaptor proteins such as
paxillin to initiate signaling (as reviewed in [70]). Src related kinases, such as Fyn
[68], are brought into physical proximity by CD36 dimerization caused by TSP-1 [71].
The cascade continues when p38 kinases are activated with subsequent activation
of caspases 3 and 7 [68]. This leads to the transcriptional activation of the fasL,
which serves as a ligand for the extrinsic death receptor CD95/Fas. This signaling
pathway is summarized in Figure 1. As signaling pathway of TSP-1 in PCa cells has
not been elucidated, the pathway in endothelial cells serves as a model for this
study.

Figure 1. Mechanisms of TSP-1
and CD36 signaling cascade in
activated endothelial cells. TSP-1
binding to CD36 stimulates CD36
dimerization which then recruits the
adaptor molecule paxilin to initiate a
signaling cascade. TSP-1 binding to
CD36 brings the src-kinase fyn to
physical proximity to CD36, allowing
activation. Activated fyn, in turn,
phosphorylates (activates) both p38
MAPK and JNK. Kinases p38 and
JNK pathways both ultimately lead
to induction of apoptosis.
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TSP-1 and PEDF interactions in other tissues
Another molecule implicated in TSP-1 signaling is PEDF. In a study by Schmitz et al,
PEDF suppresses TSP-1 levels in vitro in pancreatic cells [72]. Wang et al. observed
that TSP-1 levels were reduced in vitreous fluid of diabetics and that this decrease
was highly associated with an increase in a high molecular weight PEDF isoform
[73]. PEDF has been reported to upregulate TSP-1 production in glioma cells. Guan
et al. found that glioma cells (U251) overexpressing PEDF showed a 5.3 fold
increase in TSP-1 protein with a downregulation in VEGF and basic fibroblast growth
factor levels [74]. Consistent with the results in the glioblastoma cell line, Jia and
Waxman found that KM12/PEDF-expressing colon tumors displayed an increase in
TSP-1 levels [75]. In endometrial cancer cell lines, PEDF induced an increase in the
TSP-1 mRNA levels [76]. However, whether TSP-1 influences PEDF expression in
PCa is unknown.

Hypothesis and specific aims
PCa is the second most common type of cancer in American men and one of
the leading causes of cancer-related death worldwide [1]. The expression of
thrombospondin (TSP)-1, a multifunctional glycoprotein protein, is decreased in
many cancer types, including PCa [29]. TSP-1 is a matricellular glycoprotein
discovered first in activated platelets [48]. While it is a potent angiogenesis inhibitor,
it also has many other functions, such as activating transforming growth factor-β [53].
In many cancer types, TSP-1 is downregulated by oncogenes such as c-fos, c-jun
and Ras [77, 78]. In PCa cells, the tissue levels of TSP-1 are repressed by
androgens [63]. In addition, TSP-1 knockout mice develop prostate hyperplasia, a
precursor lesion to cancer, demonstrating the importance of this protein in
maintaining the normal prostate [56].
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TSP-1 can exert its activity through binding to CD36 [79]. The CD36 receptor
plays an important role in fatty acid and glucose metabolism and is also known as
fatty acid translocase [65, 80, 81]. The CD36 signaling pathway is mediated via src
and MAP kinase family of proteins, including fyn, p38 and JNK in other cell types
[68]. While CD36 has been shown to be overexpressed in PCa, its function is
unknown. Recent studies have shown that lipid accumulation stimulates proliferation
of PCa cells (Doll lab, unpublished observation); however, the mechanism of lipid
uptake in these cells is not established. Thus, initially, I hypothesized that TSP-1 and
CD36 regulated cellular lipid uptake. In PCa cells treated with oleic acid to induce
lipid accumulation, neither TSP-1 nor anti-CD36 antibody treatment affected lipid
accumulation, as assessed by Oil Red O (ORO) staining experiments (Figure 2).
However, I did find that treatment with either TSP-1 or neutralizing anti-CD36
antibody increased the expression of PEDF. PEDF is another potent anti-angiogenic
molecule, which is also downregulated in PCa cells. In other cell types, a regulatory
loop between TSP-1 and PEDF has been established; however, the regulation of
either protein in prostate cells is unclear. PEDF has been shown to inhibit PCa
growth through its effects on angiogenesis and directly on the PCa cells, including
induction of lipolysis [30]. Increasing PEDF expression, with TSP-1 treatment and/or
neutralizing CD36 treatment, could be a novel target for antitumor therapy in PCa.
Thus, I hypothesized that TSP-1 binding to CD36 induced PEDF and antiangiogenic activity. To test this hypothesis, I conducted the following
experiments:
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Figure 2. TSP-1 and anti-CD36 antibody treatment did not change cellular lipid
accumulation in PC-3 or DU145 cells. PC-3 (A) or DU145 (B) cells were plated on chamber
slides and left overnight to allow cell attachment. Cells were then treated with TSP-1 (1, 20 nM) or
+/- oleic acid (1 mM) or neutralizing anti-CD36 antibody (5 μg/ml). After 48h, media was aspirated
and cells were stained with Oil red O, a neutral lipid stain.

Specific aim 1: To establish that TSP-1 induces PEDF expression through inhibition
of CD36 by (a) determining if PEDF expression increases in PCa cells in presence of
TSP-1 or anti CD36 antibody treatment; (b) assessing if PEDF levels increase in the
presence of anti-CD36 siRNA treatment; and, c) comparing the levels of PEDF
expression in prostate tissues taken from TSP-1 and CD36 knockout mice to that of
wildtype mice.

Specific aim 2: To elucidate the signaling pathway through which TSP-1 and/or
CD36 regulate PEDF expression and determine if the TSP-1-induced PEDF
produces a more anti- angiogenic phenotype by (a) Examining the expression levels
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of known TSP-1 and CD36 signal mediators fyn, p38 and JNK; and, b). Evaluating
changes in secreted angiogenic activity in PCa cells treated in aim 1 above.

Through the experiments proposed here, I will begin to establish the signaling
mechanism through which PEDF expression is regulated. This pathway could be a
novel target for future PCa therapy development.
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MATERIALS AND METHODS
Cells lines and strains
PCa cell lines PC-3, DU145, LNCaP and RWPE-1, the normal prostate
epithelial cell strain, and human microvascular endothelial cells (HMVECs) were
used in these experiments. PC-3, DU145, LNCaP and RWPE-1 cells were
purchased from the ATCC (Manassas, Virginia). All the PCa cell lines were originally
isolated from metastatic lesions. DU145 and PC-3 cells are androgen refractory
while LNCaP is an androgen sensitive cell line [82]. PC-3 and DU145 cells were
grown in Dulbecco’s Modified Eagle Medium (DMEM, Sigma, St. Louis, MO, cat#
D5796) with 10% Fetal Bovine Serum (FBS, Sigma, St. Louis, MO, cat# F2442), and
1% penicillin / streptomycin (P/S, Cellgro, Manassas, VA, cat # 30-002-CI). LNCaP
cells were grown in Roswell Park Memorial Institute Medium (RPMI, Sigma, St.
Louis, MO, cat# RNBC4302) media with 10% FBS and 1% P/S. RWPE-1 cells were
grown in keratinocyte growth media (Life Technologies, Grand Island, NY cat#
10724-011) with 1% P/S. HMVECs were cultured in gelatinized tissue culture flasks.
Flasks were gelatinized overnight at 4°C by incubating the flask’s growth surface in a
0.01% solution of gelatin (Difco, Sparks, MD, cat# 214340 ) in phosphate buffered
saline (PBS, Cellgro, Manassas, VA, cat# 21-031-CV) to enhance cell adherence.
HMVECs were grown in endothelial cell growth media (EGM, Lonza, Walkersville,
MD, cat# CC-4147). All cells were maintained, and all cell experiments were
conducted, at 37C in 5% CO2.

Cell culture and treatments
For TSP-1 and anti-CD36 (αCD36) antibody treatment studies, cells were
plated at 20,000 cells / cm2 in 10 cm tissue culture dishes with growth media (day
1). These cells were left overnight to allow cell attachment. Experimental group
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media contained either TSP-1 (R&D systems, Minneapolis, MN, cat# 3074-TH) at a
dose of 1, 5, 10 or 20 nM or αCD36 antibody (Novus Biologicals, Littleton, CO, cat#
NBP1-60151) at a dose of 2 or 5 μg/ml. On day two, growth media were aspirated,
cells were rinsed with PBS, and then experimental treatment media were added.
Basal media alone served as a negative control. The cells were then incubated with
treatment media for 48 hours. At the end of the 48h treatment, cells were collected
for proliferation analysis, cell lysate collection and conditioned media collection. All
cell culture experiments were repeated at least two times.

Conditioned Media Collection
Conditioned media from treatment groups was collected for PEDF expression
analysis and for functional studies (described below). Conditioned media was
carefully pipetted from the tissue culture dishes into conical tubes on ice. These
tubes were centrifuged at 800 - 1000 x g for 8 minutes at 4C to pellet any cellular
debris. After centrifugation, conditioned media was transferred to a new conical
tube. Aliquots of each sample were then taken for the lipolysis assay (described
below). Then, 1X protease inhibitor cocktail (Sigma, St. Louis, MO, cat# P8340) and
1 µM phenylmethylsulfonyl chloride (PMSF, Sigma, St. Louis, MO, cat# 93482) were
added to the conditioned media. To capture floating cells, the tubes containing the
cell pellets were then used to collect cells for the proliferation assay (described
below).
The protein concentration in the conditioned media of these cell lines is low
(Doll et al, unpublished data). Therefore, after collection, conditioned media were
concentrated using Millipore ultra-15 centrifugal filter device with a 3 kDa cutoff value
and 15 ml volume (Millipore, Billerka, MA, cat# UFC9). The centrifugal filter was filled
with PBS and centrifuged (4000 x g) at 4C for 10 minutes to wet the membrane.
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The remaining PBS was discarded and the conditioned media was added to the
membrane. This was centrifuged (4000 x g) at 4C for 5-60 minutes, depending on
the sample volume and speed of filtration, as the membrane filter cannot be allowed
to become absolutely dry. The filtrate was discarded after each spin. Additional
conditioned media was added and centrifuged until the entire sample was included.
Then, PBS was added up to 2 times the conditioned media volume to wash out the
phenol red. Samples were then transferred to a siliconized tube and stored at -80°C
until use.

Proliferation assay
Cells were trypsinized (1 ml trypsin 10 cm per dish; Trypsin-EDTA, Cellgro,
Manassas, VA, cat# 25-053-CL) and detached cells were added to growth media (3
ml) was used to stop the trypsinization in the tube preserved above. A 50 l aliquot
of this cell solution was added to a tube containing 50 l of 0.4% trypan blue stock
solution (Sigma, St. Louis, MO, cat# T8154). After 5 minute incubation a 20 μl aliquot
was added onto a Cellometer cell counting chamber slide (Nexcelom, Lawrence,
MA, cat# SD100). A total cell and live cell count, with viability calculation, was
performed on the Cellometer (Cellometer Auto T4, Bioscience, Nexcelom, Lawrence,
MA) per the manufacturer’s instructions. Reported numbers included the dilution
factor of 2 for the dilution in trypan blue. Final total counts were calculated by
multiplying the calculated number of cells per milliliter by the total volume of cells (4
ml). Counts for each treatment group were performed in duplicate and compared to
the negative control.
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Cell lysate collection
The cells collected above were pelleted by centrifugation (800 x g for 8
minutes), and the media was aspirated. Cell lysis buffer (1x, Cell Signaling, Danvers,
MA, cat# 9803S), prepared with 1x protease inhibitor cocktail and 1 M PMSF, was
added to the pellet. Cells were mixed, and the solution was transferred to a
microfuge tube and incubated on ice for 5 minutes. Each tube was then vortexed for
15 to 30 seconds, and the samples were centrifuged at 14000 x g for 10 minutes at
4C. The supernatant was collected in a siliconized microfuge tube and stored at 80C until use.

Free glycerol assay
The principal of this assay is that during triglyceride catabolism, the liberated
glycerol is released from the cell; thus, measuring released glycerol is an indirect
measure of lipid catabolism. The aliquot of conditioned media taken above was used
in the free glycerol assay. The standards were prepared from the glycerol standard
solution (Sigma, St. Louis, MO, cat# G7793; 0.26 mg glycerol/ml) and ranged in
concentration from 0.26 to 0.0325 mg/ml. In the assay, 200 μl of the conditioned
media was added to 800 μl of free glycerol reagent (Sigma, St. Louis, MO, cat#
F6428) in a 1.5 mL disposable cuvette. The blank for the procedure was free glycerol
reagent alone. The free glycerol reagent reacts with the glycerol to produce a color
and absorbance is read at 540 nm, as detected by the spectrophotometer
(Shimadzu, Kyoto, Tokyo, model# UV-2501PC). The samples were compared to the
untreated group and normalized to total cell count for each treatment, as determined
by the proliferation assay.
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CD36 siRNA transfection
Thermo Scientific DharmaFECT siRNAs were used to test if CD36 expression
could be inhibited in the PCa cell lines. siRNA mix was prepared in RNAase free
water. All the procedures were executed per manufacturer’s protocol. Briefly, cells
were plated at 15,000 cells/cm2 in growth media (DMEM, 10% FBS, 1% P/S) and
incubated overnight. siRNA was premixed with basal media, without P/S.
Lipofectamine 2000, the transfection reagent (Invitrogen, cat # 11668), was also
premixed in basal media without P/S. Both mixes were incubated at room
temperature for 5 minutes. The two reagent mixes were then combined and
incubated for 20 minutes. The growth media on the cells was aspirated and replaced
with fresh growth media without P/S, as P/S interferes with the transfection reagent.
The transfection was performed by adding the siRNA-Lipofectamine mixture to cells
and incubating them at 37C, 5% CO2 for 24 h. The transfection media was then
aspirated, and the cells were washed with PBS and basal media with P/S was added
to cells. The cells were incubated at 37C for 48 h. After the incubation period,
conditioned media and cell lysate were collected, and cell proliferation was analyzed.
CD36 levels were analyzed by Western blot and PEDF levels were assessed by
enzyme linked immunosorbent assay (ELISA) as described below.

Protein quantification
Total protein levels in conditioned media and cell lysate samples were
quantified by the Coomassie assay using the Coomassie reagent and prediluted
BSA protein standards from Thermo-Pierce (Rockford, IL, cat# 1856209 and
#23208, respectively). The standards ranged in concentrations from 0 μg/ml to 1500
μg/ml. Samples were prepared using 10 l of conditioned media or a 1:2 dilution of
cell lysate in PBS. If the sample was too dilute, or too concentrated, the dilution was
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adjusted. The samples were incubated for 5 minutes. Each sample tube was then
compared to the high and low standard tubes to check if the sample was in range of
the standard curve. If not, a new dilution was prepared accordingly to ensure the
sample was in range of the standards. Standards or samples (200 μL) were pipetted
into the wells of a 96 well plate, with each sample in duplicate wells. The plate was
read at 595 nm using a plate reader (BioTek, Synergy HT). Sample concentrations
were calculated from the standard curve. This quantification function was
incorporated into the plate reader assay.

PEDF levels
PEDF protein levels in conditioned media and cell lysate were quantified by
Enzyme-linked immunosorbent assay (ELISA; BioProducts MD, Middletown, MD,
cat# PED613) per the manufacturer’s instructions. Briefly, all standards were
prepared by serial dilution and were pipetted in duplicate wells on the microtiter plate
(100 μl / well). After all samples (100 μl / well) and standards were added, the plate
was incubated for 1 h at 37°C. At the end of this incubation, the samples were
aspirated and each well was washed with 1X wash buffer five times using a squirt
bottle, with the final wash aspirated. PEDF detector antibody (100 μl / well) was then
added to each well except the blank wells. This was incubated for 1 h at 37°C. At the
end of incubation period, the detector antibody was aspirated and each well was
washed as above.Next, 100 μl / well of streptavidin peroxidase working solution was
added. The plate was then incubated for 30 minutes at 37°C. Post this, wells were
aspirated of their constituents and washed as above. Pre-warmed 3,3’,5,5’tetramethylbenzidine (TMB) substrate (100 μl / well) was added to all wells, and this
was incubated for 20 minutes at room temperature. Stop solution was then added
(100 μl / well) and a color change was observed from blue to yellow. The plate was
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read at 450 nm using a microplate reader (BioTek, Synergy HT), and well
concentrations were determined by reference to the standard curve. These
calculations were incorporated into the plate reader assay. Samples were compared
to the negative control, and when multiple assays were combined, samples were
compared as fold over values.

Analysis of CD36, fyn, JNK and p38 protein levels by Western blot
Forty g of each protein sample was prepared with 1X Laemmeli sample
buffer (BioRad, Hercules, CA, cat# 161-0737) in a 30 μl volume. Samples were then
incubated at 95°C to ensure denaturation and then each sample loaded on a 12%
precast acrylamide gel (Bio-Rad, Hercules, CA, cat# 456-9033). Prestained protein
marker (10 l) was also loaded as a size standard (Bio-Rad, Hercules, CA, cat# 1610374). Gels were run at 120 volts for 1.5 h in Tris-glycine-SDS buffer (Bio-Rad,
Hercules, CA, cat# 161-0732). The gel was then washed with transfer buffer (1X
Tris-glycine and 20% methanol) for 10 minutes. The proteins separated on the gel
were transferred to a solid PVDF membrane (GenHunter Corporation, Nashville, TN,
cat# B301-50) by electroblotting for 2 h at 50 volts. To block non-specific binding, the
membrane was then incubated with 1X Tris buffered saline (TBS, Sigma, St. Louis,
MO, cat# 021M6078) with 0.05% tween (Sigma, St. Louis, MO, cat# P2287), TBS-T,
and 5% dry milk at room temperature for 1 h. Post blocking, membranes were
washed twice for 10 minutes each with 50 ml of TBS-T. The membrane was then
probed with primary antibodies purchased from Cell Signaling (anti-CD36, cat#
NBP1-8392, anti-fyn, cat# 4023, anti-p38, cat# 9212 or anti-JNK, cat# 3708).
Primary antibodies were incubated in TBS and 5% bovine serum albumin (BSA)
overnight at 4°C on a shaker. The next day, membranes were washed thrice for 10
minutes each with 50 ml TBS-T. Membranes were then incubated with secondary
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antibody conjugated to horseradish peroxidase (HRP) at 1:1000 in TBS-T
(ThermoScientific, Waltham, MA, cat# 34080) for 1 h at room temperature. At the
end of 1h, membranes were washed thrice for 10 minutes each with 50 ml TBS-T.
For chemiluminescence detection, the Pierce Pico reagents (ThermoScientific,
Rockford, IL, cat# 34080) were used per manufacturer’s instructions. Blots were then
subjected to autoradiography using X-ray film for a permanent record.

Microvascular endothelial cell proliferation assay
Microvascular endothelial cells were plated in endothelial cell growth media at
5,000 cells/well in 100 μl media in a 96 well gelatinized culture plate in growth media
(day-1). Cells were incubated for 12-24 h to allow attachment. At day 0, media was
aspirated and replaced with endothelial basal media (EBM Lonza, cat#: CC-3156)
with 1% P/S with or without conditioned media samples in quadruplicate wells. For
the negative proliferation control, basal media (serum and growth factor free) was
used. For the positive control, growth media (EGM) was used. On day 7, proliferation
was

analyzed

using

the

3-(4,5-Dimethylthiazole-2-yl)-2,5-diphenyltetrazolium

bromide (MTT) reagent. Cells were aspirated of their media and 100 μl of fresh
serum-free media was added. Post this, 10 μl of MTT stock solution (Sigma, St.
Louis, MA, cat# M5655) was added to each well. The plates were then incubated at
37°C for 4 h. Following incubation, 85 μl of solution was aspirated and 50 μl of
dimethyl sulfoxide was added to each well. This solution was mixed well by pipetting
up and down. The plates were then incubated at 37°C for 10 minutes. The
absorbance of each plate was read on the microplate reader at 540 nm (BioTek,
Synergy HT). Samples were compared to the negative control for analysis.
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Mouse prostate tissue analysis
The mouse prostate is comprised of 3 lobes called the dorsal-lateral, ventral
and anterior prostate. All three lobes were collected from both wildtype C57BL/6
mice and TSP-1 knockout (KO) mice. Mice were anesthetized using isoflurane
followed by a cervical dislocation to ensure death. A midline incision down the length
of the abdomen was then performed to expose the internal organs. The intestines
were moved to the side that exposed the reproductive system. Under a dissection
microscope, the prostate lobes were excised, placed in microfuge tubes and kept on
ice. Tissue samples were weighed and Tissue Extraction Reagent I (Invitrogen,
Grand Island, NY, cat # FNN0071) was added (100 μl per lobe) to the tissue. Tissue
was homogenized using a hand-held Kontes pellet pestle motor and disposable
pestles (Fischer Scientific, Waltham, MA, cat# KT 749540 and cat# KT-7495211590, respectively) for 1 minute on ice. The sample was then centrifuged at 10,000
rpm for 5 minutes at 4C to pellet cellular debris. The supernatant was collected and
stored in a siliconized tube at -80°C until analysis. PEDF levels were quantified by
ELISA as described above.

Statistical analysis
Statistical significance of the data was determined using ANOVA and Student
t- tests with P values < 0.05 considered significant. Analysis was computed using the
Systat statistical software incorporated into SigmaPlot program (version 12.0).
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RESULTS
Specific aim 1: To establish that TSP-1 induces PEDF expression through inhibition
of CD36 by (a) Determining if PEDF expression increases in PCa cells in presence
of TSP-1 or anti-CD36 antibody treatment; (b) Assessing if PEDF levels increase in
the presence of anti-CD36 siRNA treatment; and, (c) Comparing the levels of PEDF
expression in prostate tissues taken from TSP-1 and CD36 knockout mice to that of
wildtype mice.

A. Results for specific aim 1a
For TSP-1 and anti-CD36 antibody treatment studies, cells were plated on
day 1, and treated with either TSP-1 at a dose of 1, 5, 10 or 20 nM or neutralizing
anti-CD36 antibody at a dose of 2 or 5 μg/ml. Basal media alone served as a
negative control. At the end of the 48 h treatment, cells were collected for
proliferation analysis and cell lysate and conditioned media were collected. All cell
culture experiments were repeated at least two times.

Part 1. TSP-1 Treatment
The effect of TSP-1 treatment on cell proliferation and viability
Limitless replicative potential is a key hallmark of cancer [59]. Proliferative
activity is constantly kept in check in normal cells by endogenous inhibitors and cell
cycle regulators, as reviewed in [59]. Loss of TSP-1 expression has been associated
with a proliferation advantage in PCa cells [29]. TSP-1 expression mediates antiangiogenic activity in normal and cancerous prostatic epithelia [46, 47, 83]. To
determine if TSP-1 treatment affected cell proliferation of the normal prostate
epithelial cell line (RWPE-1) or of PCa cell lines (LNCaP, PC-3 and DU145) direct
cell counts were performed, with a trypan blue exclusion assay, on a Cellometer. In
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RWPE-1 cells, TSP-1 treatment did not significantly change total cell number when
compared to untreated cells (Figure 3A). Similarly, there was not a significant
change in the viability of these cells upon treatment with TSP-1 (Figure 3B).
Interestingly, LNCaP cells showed a significant increase in total cell count with TSP1 treatment at all doses as compared to untreated (Figure 4B; P≤0.05), while there
was no change in cell number with TSP-1 treatment compared to untreated (Figure
4B).

Figure 3. The effect of TSP-1 treatment on proliferation and viability of RWPE-1 cells. Total
cell number and viability were determined in RWPE-1 cells after TSP-1 treatment. (A) Total cell
number was measured by direct cell counts on a Cellometer and data presented as fold over
untreated. (B) Viability was determined on the Cellometer with a trypan blue exclusion assay. The
results presented in each graph are the combination of independent two experiments. No
statistically significant differences were observed.

Figure 4. The effect of TSP-1 treatment on proliferation and viability of LNCaP cells.
Total cell number and viability was determined in LNCaP cells after TSP-1 treatment. (A)
Total cell number was measured by direct cell counts on a Cellometer and data presented
as fold over untreated (*significantly increased compared to untreated, P≤0.05, (B) Viability
was determined by trypan blue exclusion assay on the Cellometer, and there was no
difference between treatment groups. Each experiment was performed at least 2 times with
similar results.
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When the more aggressive cell line, PC-3, was analyzed for cell proliferation,
a biphasic response to TSP-1 treatment was observed (Figure 5A; P≤0.041). There
was an increase in proliferation at the TSP-1 5 nM dose accompanied by a decrease
at the 10 nM dose. However, the viability of PC-3 cells was unaffected by the TSP-1
treatment (Figure 5B). In contrast to the PC-3 cells, proliferation in DU145 cells was
significantly decreased at the 1, 10 and 20 nM doses as compared to untreated
(P≤0.031; Figure 6A). The viability in DU145 cells with TSP-1 treatment showed a
modest dose-responsive increase (ANOVA, P=0.014; Figure 6B). These results
demonstrate that the effects of TSP-1 are variable, depending on cell line. With the
normal cell line, RWPE-1, no effect was seen on neither cell proliferation nor viability.
An increase in LNCaP cell number, with no change in cell viability, suggests that
TSP-1 increases the rate of mitosis.

Figure 5. The effect of TSP-1 treatment on proliferation and viability in PC-3 cells. Total
cell number and viability was determined in PC-3 cells after TSP-1 treatment. (A) Total cell
number was measured by direct cell counts on a Cellometer and data presented as fold over
untreated (*significantly increased compared to untreated, P= 0.041; **significantly decreased
compared to untreated, P= 0.018). (B) Viability was determined on the Cellometer with trypan
blue exclusion assay. No significant differences were observed between treatment groups.
The experiment was performed at least 2 times with similar results.
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DU145

DU145

Figure 6. TSP-1 treatment decreased total cell count but increased viability in DU145
cells. Total cell number and viability was determined in DU145 cells after TSP-1 treatment. (A)
Total cell number was measured by direct cell counts on a Cellometer and data presented as
fold over untreated (* P≤ 0.031 compared to untreated). (B) Viability was determined on the
Cellometer with trypan blue exclusion assay. Viability illustrated a dose response relationship
between treatment groups (*P= 0.014 by ANOVA).

The effect of TSP-1 treatment on PEDF levels
Previous studies have shown that PEDF regulates lipid metabolism in PCa
cells (Doll et al, unpublished observation). Based on my hypothesis, TSP-1 binding
to the CD36 receptor would increase PEDF levels. To test this hypothesis, PEDF
levels were quantified by ELISA in both the serum-free conditioned media and cell
lysates of TSP-1 treated cells.
In RWPE-1 cells, repeat experiments produced somewhat differing results for
PEDF expression. In the first experiment, an increase in PEDF expression was seen
with 1, 5 and 20 nM TSP-1 doses, but not in the 10 nM dose (P≤0.05; Figure 7A). In
the repeat experiment, there was a modest decrease in PEDF expression observed
at the 1 nM dose; however, an increase in PEDF levels were observed at the 10 nM
dose as compared to untreated (P≤0.05; Figure 7B). Although PEDF levels between
experiments varied, it seems that the overall effect of TSP-1 was to increase
secreted PEDF in these cells. In contrast, TSP-1 appeared to decrease PEDF in the
cell lysates at 5-20 nM TSP-1 (Figure 7C; P≤0.05), although this effect was not
observed in a repeat experiment (Figure 7D).

24

In LNCaP PCa cells, TSP-1 treatment showed a steady increase in PEDF
levels in the serum-free conditioned media; however, this only reached significance
at the 5 and 20 nM doses as compared to untreated cells (P≤ 0.037; Figure 8A). In
the cell lysates, low dose TSP-1 (1 nM) decreased PEDF levels; however, 20 nM
TSP-1 increased PEDF levels (P≤0.043; Figure 8B). Similarly to the results obtained
for LNCaP cells, TSP-1 treatment increased PEDF in both the serum free
conditioned media and in the cell lysates of PC-3 cells, although only the cell lysate
data reached statistical significance (ANOVA, P=0.009; Fig 8C,D). In DU145 cells, a
dose response increase in PEDF expression was seen in the serum free conditioned
media with TSP-1 treatment (ANOVA, P=0.004; Figure 8E). However, with low dose
TSP-1 (1nM) intracellular PEDF expression was decreased compared to untreated
cells, but at higher doses, it was not significantly changed (1nM, P≤0.015; Figure
8F). These data show that, overall, TSP-1 treatment increased PEDF expression in
all the PCa cell lines tested.

Figure 7. The effects of TSP-1 treatment on secreted and intracellular PEDF levels in
RWPE-1 cells. After TSP-1 treatment, serum free conditioned media (A & B) and cell lysate
(C & D) were collected and PEDF levels were measured by ELISA. The data are represented
as fold over untreated (*P≤ 0.05, **P≤ 0.05, ***P≤ 0.05 compared to the untreated sample).
Results shown are two experimental repeats on this cell line, which show differing results.
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Figure 8. TSP-1 treatment effect on secreted and intracellular PEDF levels in PCa cells.
After TSP-1 treatment, conditioned media and cell lysates were collected and PEDF levels
were measured by ELISA. Data is represented as fold over untreated. (A) In LNCaP cells,
TSP-1 increased PEDF expression in serum free conditioned media (*P≤ 0.037 compared to
untreated). In the cell lysate (B) PEDF expression decreased at 1 nM and increased at 20 nM
(*P≤ 0.043, **P<0.05). (C) In the serum free conditioned media from PC-3 cells, no change in
PEDF expression was observed however, in the cell lysate, a dose-response relationship with
increasing PEDF was seen (*P= 0.009) (D). In the serum free conditioned media from DU145
cells (E), a dose-response increase was observed (*P≤ 0.015). In the cell lysate (F), PEDF
expression at was decreased 1 nM dose (*P≤ 0.015). Each experiment was done twice and
similar results were obtained.

The effects of TSP-1 on lipolytic activity
The class B scavenger receptor CD36 recognizes a large variety of ligands ,
such as free fatty acids and oxLDL [80], and it functions in lipid uptake in endothelial
cells [66, 80]. Moreover, CD36-null mice have an altered lipid profile [84]. However,
as illustrated in Figure 2A and B, neither TSP-1 nor anti-CD36 antibody treatment
altered lipid uptake in PC-3 and DU145 cells. According to my hypothesis, TSP-1
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inhibitory binding to the CD36 receptor increases PEDF levels in prostate cells.
Because PEDF has been previously shown to increase lipolysis in PCa cells (Doll et
al., unpublished observation), I measured lipolysis in TSP-1 treated cells using the
free glycerol assay to quantify lipolytic activity. In RWPE-1 cells, TSP-1 increased
lipolytic activity in a dose response manner (ANOVA, P=0.001; Figure 9A). Similarly,
LNCaP cells also displayed a dose responsive increase with TSP-1 treatment
(ANOVA P≤ 0.011; Figure 9B). In PC-3 cells, while there was a modest decrease in
lipolytic activity at the lowest TSP-1 dose (1 nM; P=0.037), the 10 and 20 nM doses
significantly increased lipolytic activity compared to untreated cells, with the highest
activity at the 10 nM (P≤0.015; Figure 10A). In contrast to PC-3 cells, in DU145 cells,
TSP-1 treatment decreased lipolytic activity significantly at the 1, 10 and 20 nM TSP1 doses as compared to untreated cells (P≤0.001; Figure 10B). These data show
that in normal prostate epithelial cells, as well as in the LNCaP and PC-3 PCa cell
lines tested, TSP-1 stimulates lipid catabolism, but that in DU145 cells, the opposite
effect occurs.

Figure 9. TSP-1 treatment increased lipolytic activity in RWPE-1 and LNCaP cells.
Free glycerol levels were measured in serum free conditioned media collected after
TSP-1 treatment in RWPE-1 (A) and LNCaP (B) cells. All measures were normalized to
cell count and compared to untreated as fold over values (*P≤0.011 by ANOVA). Each
experiment was performed twice with similar results.
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Figure 10. TSP-1 treatment had variable effects on lipolytic activity in PC-3 and
DU145 cells. Free glycerol levels were measured in serum free conditioned media
collected after TSP-1 treatment in PC-3 cells (A) and DU145 cells. (B) All measures were
normalized to cell count and compared to untreated as fold over values (*P=0.037; **
P<0.001; ***P<0.001). Each experiment was performed twice with similar results.

Part 2. CD36 treatment
Effect of CD36 inhibition on cell proliferation
It has been previously shown that TSP-1 binding to CD36 blocks lipid uptake
in endothelial cells [80] and promotes apoptosis [64]. CD36 is overexpressed in PCa
cells [85], but its role in tumorigenesis remains unclear. To determine if blocking the
CD36 receptor affected proliferation of normal prostate epithelial cells or of PCa
cells, direct cell counts were performed, with a trypan blue exclusion assay, as
described above for TSP-1 treatments. In RWPE-1 cells, blocking the CD36 receptor
decreased cell proliferation; however, significance was only achieved with the 5
μg/ml dose compared to untreated cells (P=0.036; Figure 11A). Similarly, cell
viability was also decreased at all doses of the antibody compared to untreated
(P≤0.007; Figure 11B). LNCaP cells presented with a similar pattern, with decreasing
proliferation with neutralizing CD36 antibody treatment; however, the data did not
achieve significance (Figure 12A).

Viability in the LNCaP cells was decreased

significantly in a dose-dependent manner by the antibody treatment (ANOVA,
P=0.001; Figure 12B).
In PC-3 cells, blocking the CD36 receptor did not significantly change
proliferation when compared to untreated (Figure 13A). Similarly, there was no
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significant change in viability in these cells with CD36 receptor inhibition (Figure
13B). Similar to the PC-3 cells, in DU145 cells, treatment with blocking anti-CD36
antibody did not significantly change total cell number when compared to untreated
cells (Figure 14A). Interestingly, however, viability in DU145 cells was decreased in a
dose-dependent manner with CD36 receptor blockade (ANOVA, P=0.037; Figure
14B), Thus, in these cells, CD36 blockade may be increasing apoptosis or another
cell death pathway.

Figure 11. Blocking CD36 receptor decreased proliferation and viability in RWPE-1
cells. Total cell number and viability was determined in RWPE-1 cells after neutralizing
anti-CD36 antibody treatment. (A) Total cell number was measured by direct cell counts
on a Cellometer and data are presented as fold over untreated (*P= 0.036). (B) Viability
was determined on the Cellometer with trypan blue exclusion assay (*P= 0.001 by
ANOVA). Each experiment was done twice and similar results were obtained.

Figure 12. Blocking the CD36 receptor did not change proliferation but decreased
the viability of LNCaP cells. Total cell number and viability was determined in LNCaP
cells after neutralizing anti CD36 antibody treatment. (A) Total cell number was
measured by direct cell counts on Cellometer and daaa presented as fold over
untreated. Though a tend toward decrease was observed, results were not statistically
significant (P=0.057 by ANOVA). (B) Viability was determined on the Cellometer with
trypan blue exclusion assay. A dose responsive decrease in viability was observed with
anti-CD36 antibody treatment (*ANOVA, P= 0.001). Each experiment was performed
twice and similar results were obtained.
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Figure 13. Blocking the CD36 receptor did not alter proliferation or viability of PC3 cells. Total cell number and viability were determined in PC-3 cells after neutralizing
anti-CD36 antibody treatment. (A) Total cell number was measured by direct cell counts
on a Cellometer and data presented as fold over untreated. The slight increase at the 5
μg/ml dose was not statistically significant. (B) Viability was determined on the
Cellometer with trypan blue exclusion assay. No significant differences were observed
with treatment. Each experiment was done twice and similar results were obtained.

Figure 14. Blocking CD36 receptor results did not change proliferation but decreased
viability of DU145 cells. Total cell number and viability were determined in DU145 cells after
anti-CD36 antibody treatment. (A) Total cell number was measured by direct cell counts on a
Cellometer and data presented as fold over untreated. (B) Viability was determined on the
Cellometer with trypan blue exclusion assay (*P= 0.037 by ANOVA). Each experiment was
done twice and similar results were obtained.

Effect of CD36 inhibition on PEDF levels
To establish if blocking the CD36 receptor in PCa cells increases PEDF expression,
PEDF levels were quantified by ELISA in both the serum-free conditioned media and
cell lysates collected from neutralizing anti-CD36 antibody treated cells. In the
normal prostate epithelial cell line, RWPE-1, there was an increase in secreted
PEDF levels at the 5 μg/ml dose compared to untreated cells (P=0.002; Figure 15A).
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In LNCaP PCa cells, blocking the CD36 receptor resulted in a modest increase in
secreted PEDF at both doses of the antibody; however, significance was only
achieved at the lower dose (P=0.042; Figure 15B). Similarly, PC-3 cells showed a
significant increase in PEDF expression at both doses of neutralizing antibody in the
serum free conditioned media (P=0.007; Figure 15C). Likewise, in DU145 cells, there
was a significant dose-responsive increase in PEDF levels in the serum free
conditioned media when cells were treated with anti-CD36 antibody (ANOVA
P≤0.001; Figure 15D).
For several of the cell lines, the opposite results were observed in the cell
lysate. In the RWPE-1 cell lysate, a high dose (5 μg/ml) of the antibody decreased
PEDF expression (P≤0.05; Figure 15E). Interestingly, in the LNCaP cell lysate, a low
dose of neutralizing anti-CD36 antibody (2 μg/ml) increased PEDF expression
(P=0.022; Figure 15F), while the higher dose decreased it compared to untreated
cells (P=0.005; Figure 15F). In PC-3 cell lysate, PEDF expression was increased at
both doses of neutralizing anti-CD36 antibody (P≤0.001; Figure 15G). In the DU145
cell lysate, PEDF expression was decreased at the low dose (2 μg/ml) as well as the
high dose; however, significance was only achieved with the low dose (P≤0.022;
Figure 15H).
These data suggest that, overall, blocking the CD36 receptor stimulates
secreted PEDF expression in all prostate cell lines tested. There was more variability
in the levels of intracellular PEDF with CD36 treatment. While it was largely
increased at low doses (2 μg/ml) across the cell lines, the higher dose decreased
intracellular PEDF levels in RWPE-1 and LNCaP cells while increasing it in PC-3
cells.
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Figure 15. Blocking the CD36 receptor increases secreted PEDF levels. After neutralizing
anti-CD36 antibody treatment, serum-free conditioned media and cell lysates were collected
and PEDF levels were measured by ELISA. Data is represented as fold over untreated.
Results for RWPE-1 (A,E), LNCaP (B,F), PC-3 (C,G) and DU145 (D, H) are shown for both
conditioned media (A-D) and cell lysate (E-H) samples. PEDF levels increased in serum free
conditioned media and some cell lysates compared to untreated (*P≤ 0.022). In DU145 cells,
serum free conditioned media (D), the increase was dose responsive (***ANOVA P≤ 0.001).
However, PEDF levels were decreased compared to untreated, P≤ 0.051.
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Effect of CD36 inhibition on lipolytic activity
Because CD36 regulates PEDF levels and PEDF is known to increase
lipolysis in PCa cells (Doll et al. unpublished data), I evaluated lipolytic activity in
PCa cells upon blocking the CD36 receptor. I used the free glycerol reagent to
quantify this activity for the TSP-1 treatments.
In RWPE-1 cells, there was a dose-responsive increase in lipolytic activity
with neutralizing anti-CD36 antibody treatment (ANOVA P≤0.001; Figure 16A).
Similarly, LNCaP cells also displayed an increase in lipolytic activity with increasing
neutralizing anti-CD36 antibody doses; however, the data did not achieve
significance (Figure 16B). Likewise, in PC-3 cells, lipolytic activity was increased
with both doses of neutralizing anti-CD36 antibody (P≤0.001; Figure 17A). In
contrast, when the CD36 receptor was blocked in DU145 cells, a significant
decrease in lipolysis was seen at the 5 μg/ml dose (P≤0.001; Figure 17B).

Figure 16. Blocking the CD36 receptor increased lipolytic activity in RWPE-1 cells and
LNCaP cells. Free glycerol levels were measured in serum free conditioned media after
neutralizing anti-CD36 antibody treatment in RWPE-1 (A) and LNCaP cells (B). All
measures were normalized to cell count and compared to untreated as fold over values. In
(A), lipolytic activity was significantly increased in a dose responsive manner (*P≤ 0.010 by
ANOVA). The increase observed in LNCaP cells (B), was not statistically significant. Each
experiment was performed twice with similar results.
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Figure 17. Blocking the CD36 receptor increased lipolytic activity in PC-3 cells but
decreased it in DU145 cells. Free glycerol levels were measured in serum free conditioned
media after neutralizing anti-CD36 antibody treatment in PC-3 (A) and DU145 cells (B). All
measures were normalized to cell count and compared to untreated as fold over values. In
PC-3 cells (A), lipolytic activity was significantly increased at both doses of antibody (*P≤
0.001). In DU145 cells (B), lipolytic activity was significantly decreased at the 5 μg/ml dose,
(*P≤ 0.001). Each experiment was performed twice with similar results.

B. Results for Specific aim 1b:
This aim was pursued to investigate if PEDF expression increased in PCa
cells when CD36 receptor expression was blocked using an siRNA approach. I
tested four different siRNAs against CD36 for this assay. DU145 cells were used to
test this assay because blocking the CD36 receptor in these cells resulted in an
increased secreted PEDF expression. Cells were plated overnight, transfected with
siRNA on day 2 and then incubated for 2 days in basal media. On day 5, cell lysates
and serum free conditioned media were collected to assay for CD36 and PEDF
levels as well as cell proliferation and viability. GAPDH siRNA was used as a
negative control for siRNA activity in this assay.
To confirm CD36 suppression, I performed a Western blot using anti-CD36
antibody on the cell lysates. Two different anti-CD36 antibodies were tested;
however, due to technical difficulties with the assay and antibody, I was not able to
confirm CD36 suppression (data not shown). Despite this, I still assessed cell
proliferation and PEDF levels in these samples. Although several of the CD36
siRNAs suppressed total cell numbers (P≤0.013; Figure 18A; clone 7 at 10 nM; clone
8 at 10 nM and clone 9 at both 5 and 10 nM), cell numbers were also decreased with
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the GAPDH siRNA at 5 nM as compared to untreated (P=0.026; Figure 18A), making
any conclusions difficult. Conversely, none of the siRNAs affected cell viability
(Figure 18B).
A PEDF ELISA was performed on the CD36 siRNA treated serum-free
conditioned media and cell lysate samples. While siRNA against CD36 receptor
diminished PEDF levels in serum-free conditioned media (P≤ 0.023; Figure 19A;
clones 7,8 and 9 at both 5 and 10 nM; and clone 10 at 5 nM), the non-targeting
siRNA used (GAPDH) also decreased secreted PEDF, so the significance of this
data cannot be determined. Interestingly, the PEDF expression in the cell lysate was
slightly increased with clone 8 at the 10 nM dose (P= 0.047; Figure 19B). Overall, an
accurate interpretation of these results will not be possible until the CD36 levels can
be assessed in these samples; however, the data with the GAPDH siRNA suggests
that the assay needs to be further optimized to decrease non-specific effects.

Figure 18. siRNA against CD36 receptor decreased proliferation in DU145 cells. Cell were
plated overnight and then transfected with anti-CD36 siRNA for 24h. After additional 48h
incubation, Total cell number and viability were determined after anti-CD36 siRNAtreatment. (A)
Total cell number was measured by direct cell counts on a Cellometer. All measures were
compared to untreated (*P≤ 0.026). (B) Viability was determined on the Cellometer with trypan
blue exclusion assay. There was no significant different between samples. Note: this experiment
was performed only one time.
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Figure 19. The effect of anti-CD36 siRNA on PEDF levels in DU145 cells. Cell were plated
and transfected with anti-CD36 siRNA. PEDF ELISA was performed on the serum free
conditioned media and cell lysate samples collected. (A) There was a decrease in secreted
PEDF protein with all anti-CD36 clones, when compared to untreated (*P≤ 0.023). In cell
lysate (B), one CD36 siRNA clone (clone 8) at the 10 nM (clone 8), *P= 0.047.

Results for specific aim 1c:
In order to analyze if the loss of TSP-1 expression altered PEDF protein levels
in vivo, I proposed to evaluate PEDF levels in TSP-1 and CD36 KO mice. However,
due to prohibitive costs, CD36 knockout mouse tissues were not examined. I
collected age-matched TSP-1 KO and wildtype prostate tissues by microdissection.
The ventral and dorsolateral prostate lobe tissues were initially frozen and stored.
Tissues were homogenized and proteins were extracted and examined by PEDF
ELISA. Tissues were examined from mice at both 4 and 6 months of age and data
were normalized to total protein content.
In 4 month old mice, there was a small trend toward a decrease in PEDF
expression in both the ventral prostate and dorsolateral prostate of the TSP-1 KO
(n=3) compared to the wildtype mice (n=3); however, data were not statistically
significant (Figure 20A). At 6 months of age, there was no significant change in the
PEDF expression levels between the TSP-1 KO (n=4) and age matched wildtype
mice (n=4) (Figure 20B). Due to the large variations within the samples and the small
sample size of the experiment, future experiments are needed to increase the
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number of tissues analyzed per group to confirm whether or not loss of TSP-1 affects
PEDF levels in the prostate in vivo.

Figure 20. Loss of TSP-1 expression did not alter in PEDF expression in mouse
prostate tissues. The ventral prostate (VP) and dorsolateral prostate (DLP) were
collected from TSP-1 KO and wildtype mice, age matched at 4 months, n= 5 WT, 4
TSP-1 KO (A) and 6 months, n= 3 WT, 3 TSP-1 KO (B). PEDF levels were analyzed by
ELISA. There was no statistically significant difference between the PEDF levels in the
TSP-1 KO VP or DLP, as compared to wildtype VP and DLP.

Specific aim 2
To elucidate the signaling pathway through which TSP-1 and/or CD36 regulate
PEDF expression and determine if the TSP-1-induced PEDF produces a more antiangiogenic phenotype by (a) Examining the expression levels of known TSP-1 and
CD36 signal mediators fyn, p38 and JNK; and, b) Evaluating changes in secreted
angiogenic activity in PCa cells treated in aim 1 above.

Results for specific aim 2a
As depicted in Figure 1, the signaling molecules that mediate the TSP-1 CD36 activity in endothelial cells are JNK, p38 MAPK and fyn [68]. This signaling
pathway, however, has not been investigated in PCa cells. To investigate the
potential role of signaling molecules in the TSP-1 - CD36 pathway, Western blot
analysis was performed to detect the expression levels of these molecules in cell
lysate samples derived from PC-3 and DU145 PCa cells treated with TSP-1 or anti-
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CD36 antibody from Aim 1a. All protein levels were compared to GAPDH levels as a
control for equal protein loading. No fyn was detected in untreated DU145 or PC-3
cells (Figure 21A,B). TSP-1 treatment did modestly increase fyn expression,
particularly at the higher dose in both cell lines (Figure 21A,B). Neutralizing antiCD36 antibody did not increase fyn levels in either cell line (Figure 21A,B).
My data shows that p38 was expressed in untreated PC-3 and DU145 cells
(Figure 21A,B). However, TSP-1 treatment did not change p38 expression in either
DU145 or PC-3 cells. In contrast, neutralizing anti-CD36 antibody decreased p38
expression at both doses in both DU145 and PC-3 cells (Figure 21A,B).
JNK was expressed in DU145 untreated cells (Figure 21A). However, in PC-3
cells, JNK expression was barely detectable in untreated cells (Figure 21B). TSP-1
treatment did not alter JNK expression in DU145 cells across all doses except at 5
nM, which showed decreased expression (Figure 21A). In PC-3 cells, TSP-1
treatment modestly increased JNK expression at 5 and 10 nM (Figure 21B).
Neutralizing anti-CD36 antibody had no discernable effect on JNK expression at
either dose in PC-3 cells (Figure 21B). However, in DU145 cells, JNK expression
was diminished at 2 μg/ml of neutralizing anti-CD36 antibody (Figure 21A). These
data suggest that TSP-1 treatment induces expression of p38 MAPK, fyn and JNK in
PCa cells. While, blocking CD36 receptor diminishes the expression of JNK and p38.
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Figure 21. TSP-1 and anti-CD36 treatment alter intracellular signaling in prostate cancer
cells. DU145 (A) and PC-3 (B) cells were treated with either TSP-1 or neutralizing anti-CD36
antibody in serum-free media for 48 h. Cell lysates were collected, quantified, and total proteins
separated by SDS-PAGE (12% gel) samples were then electroblotted to a PVDF membrane and
probed with the indicated antibody. GAPDH served as a control for protein loading. U, untreated;
MW, Molecular weight markers (in kDa).

Results for specific aim 2b
To assess if TSP-1 treatment or blocking the CD36 receptor altered secreted
angiogenic activity by prostate cells, I measured human microvascular endothelial
cell (HMVEC) proliferation, by MTT assay. The samples tested were the serum-free
conditioned media derived from LNCaP, RWPE-1, PC-3 and DU145 cells across
different doses of TSP-1 and neutralizing anti-CD36 antibody collected in Aim 1a
above. Endothelial cell growth media served as a positive control for this assay,
while basal media served as the negative control. TSP-1 treatment did not alter the
angiogenic activity, as measured by HMVEC proliferation, in any of the four cell lines
(Figure 22A-D). Similarly, angiogenic activity was not altered in any of the four cell
lines by neutralizing anti-CD36 antibody treatment (Figure 23A-D) However, these
assays were only performed one time; thus, repeat experiments are needed to
confirm the results obtained.

39

Figure 22. TSP-1 treatment did not alter secreted angiogenic activity of normal prostate
epithelial or prostate cancer cells. Endothelial cell were plated in 96 well plates overnight and
serum-free conditioned media (CM) derived from cells treated with TSP-1 was added to the wells.
After 7 days, an MTT assay was performed and read on the plate reader. In RWPE-1 (A), PC-3
(B), LNCaP (C) and DU145 (D), there was no change in the endothelial cell proliferation. The
negative control was basal media alone, and TSP-1 alone was tested alone as an additional
control at 1, 5, 10 and 20 nM doses with no change on proliferation (data not shown).

Figure 23. Anti-CD36 treatment did not alter secreted angiogenic activity of prostate
cells. Endothelial cell were plated in 96 well plates overnight and serum-free conditioned
media (CM) derived from PCa cells treated with αCD36 antibody was added to the wells.
After 7 days, MTT assay was performed and read on the plate reader. In RWPE-1 (A), PC-3
(B), LNCaP (C) and DU145 (D), there was no change in the endothelial cell proliferation with
treatment. The negative control was basal media. Anti-CD36 antibody was tested at both the
2 and 5 μg/ml dose with no change on proliferation (data not shown).
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DISCUSSION
The purpose of these studies was to determine if the TSP-1 - CD36 pathway
regulates PEDF expression and angiogenic activity in prostate cells. TSP-1 and
PEDF are both potent angiogenic inhibitors that are downregulated in PCa tissues
[57, 86, 87]. In endothelial cells, TSP-1 mediates its anti-angiogenic activity via by
binding to the CD36 receptor [88]. Studies in other tissues have established a
regulatory loop between TSP-1 and PEDF. Guan et al. found that, when PEDF was
overexpressed in glioma cells (U251), there was a 5.3 fold increase in TSP-1
expression [74]. Consistent with these results, Jia and Waxman found that KM12
colon tumor cells expressing PEDF displayed an increase in TSP-1 levels [75]. Also,
in endometrial cancer cell lines, PEDF induced an increase in TSP-1 mRNA levels
[76]. In a study by Aparicio et al. human umblical vein endothelial cells exposed to
cobalt chloride showed a reduction in TSP-1 transcripts and treatment with PEDF
blocked this reduction [89]. Contrarily, Schmitz et al. show that PEDF overexpression
in pancreatic cancer cells was associated with suppression of TSP-1 levels [72].
However, if TSP-1 influences PEDF expression in tissues is unknown, and no
studies have illustrated the effects of TSP-1 treatment on PEDF expression on
normal prostate epithelial cells or in PCa cells. In this study I hypothesized that TSP1 - CD36 binding would stimulate PEDF expression.
In specific aim 1, I showed that TSP-1 treatment increased secreted PEDF
protein expression in LNCaP and DU145 cells. In addition, the protein expression in
PC-3 cells was somewhat increased but did not reach statistical significance. When
treated with neutralizing anti-CD36 antibody, all of the PCa cells used in this study
showed an increase in secreted PEDF expression. My data also suggested an
overall increase in cellular PEDF expression levels in prostate cell lines at lower
dose of the antibody, with the exception of DU145 cells.
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PEDF has been most well studied as a secreted anti-angiogenic protein, and
an increase in secreted PEDF may be linked to an increase in anti-angiogenic
activity [39]. However, some studies have also detected intracellular protein levels
and even nuclear staining [90-92]. Studies on retinoblastoma, neuroblastoma,
hepatocarcinoma and retinal pigment epithelial cells have shown both cytoplasmic
and nuclear PEDF expression levels [93]. Based on this, Anguissola et al. suggest
that PEDF should be included in human serpins that demonstrate nucleocytoplasmic
distribution such as antichymotrypsin and antiangiotensinogen [94]. Although a clear
demarcation in function between secreted and intracellular PEDF expression is not
well established, it is believed that the intracellular PEDF expression is linked to
regulation of lipolytic activity in the cell [95]. My studies illustrate that LNCaP and
RWPE-1 cells showed an increase in lipolytic activity with TSP-1 doses. DU145 cells
showed a decreased lipolytic activity. Blocking the CD36 receptor in PC-3, LNCaP
and RWPE-1 cells showed an increase in lipolytic activity. However, DU145 cells
showed decreased lipolytic activity. CD36 signaling blocks lipolysis in most PCa cells
and in normal prostate epithelial cells. However, the decreased lipolytic activity in
DU145 cells suggests that a underlying difference in genetic background specific to
this line alters the lipolytic signaling pathway.
Since tumor progression is guided by several factors such as cell proliferation,
I determined whether treatment with TSP-1 or anti-CD36 antibody was altering cell
proliferation and viability of prostate cells. My cell proliferation data showed that
TSP-1 treatment did not alter the total cell number or viability in RWPE-1 cells. Data
obtained from LNCaP cells revealed that there was an increase in total cell count
with all the TSP-1 doses, although viability was unaffected. Thus, these data would
be consistent with TSP-1 promoting cancer progression in the LNCaP cell model.
Migration is another necessary phenotype for cancer progression and a study by
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Firlej et al. reported that TSP-1-mimetic ABT-510 increases migration in LNCaP cells
by 3.5 fold [96]. In the more aggressive cell lines, PC-3 and DU145, I observed that
cell proliferation was decreased at higher doses of TSP-1. In contrast, Jin et al.
reported that DU145 cells showed no change in cell proliferation when TSP-1 was
overexpressed by a plasmid clone in these cells [97]. Most studies have, however,
shown that TSP-1 is correlated with anti-angiogenic activity and better prognosis [57,
98-100], although some suggest that TSP-1 expression is positively correlated with
increased angiogenesis and poorer prognosis in human cancer tissues [101, 102].
My data in PC-3 and DU145 cells are consistent with an anti-tumor role for TSP-1 in
PCa.
As CD36 is known to regulate fatty acid uptake in other cell types, it was
interesting to note that neither TSP-1 nor neutralizing anti-CD36 antibody affected
lipid accumulation in PC-3 and DU145 cells. In a study by Borg et al. PEDF was
found to regulate systemic fatty acid metabolism by promoting lipolysis in an adipose
triglyceride lipase-dependent manner [44] and other studies showed that PEDF
induced lipolysis in PCa cells (Doll et al. unpublished data). Therefore, since I
observed an increase in PEDF, I analyzed the effects of TSP-1 or anti-CD36
antibody treatment on lipolysis. Interestingly, TSP-1 treatment increased lipolytic
activity in a dose responsive manner. An increase in lipolytic activity was also seen
at higher doses of TSP-1 in PC-3 and LNCaP cells; however, in DU145 cells TSP-1
decreased lipolysis. This suggests that TSP-1, while it does not affect lipid uptake,
does affect lipid catabolism in some prostate cells. Lipolytic activity also increased
when the CD36 receptor was blocked in RWPE-1, PC-3 cells and a trend was also
seen in LNCaP cells. However, this effect was not seen with DU145 PCa cells.
PEDF has been shown to influence systemic lipid metabolism in other cell types [44]
and therefore, the work presented here, on prostate cells is consistent with the
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published literature. Further studies, in which PEDF is blocked, are needed to
determine if PEDF is necessary for the increased lipolytic activity in RWPE-1,
LNCaP and PC-3 cells.
Disparities observed in TSP-1 and anti-CD36 antibody responses between
the prostate cell lines examined in this study are most likely due to the background of
genetic mutations. The aggressive cell line PC-3 and DU145 are androgen
refractory, as opposed to LNCaP cells, which are androgen sensitive. DU145 cells
are known to express the wildtype PTEN protein, a key tumor suppressor gene, as
opposed to PC-3 cells, which express mutant protein [103, 104]. PTEN plays a
crucial role in cell growth and proliferation. Most human PCa are mutant for this
protein, thereby aiding the process of tumorigenesis [105, 106]. Both of these
aggressive cell lines, PC-3 and DU145, are also mutant for the well known p53
tumor suppressor gene [82]. The less aggressive PCa cell line, LNCaP, is mutant for
PTEN but expresses p53. In addition, while PC-3 and LNCaP cells express wildtype
retinoblastoma (Rb), DU145 cells express mutant Rb protein [82]. These genetic
differences are summarized in Table 1. Many other mutational differences exist
between these cell lines, which could, at least in part, explain the differences in
PEDF response to TSP-1 and anti-CD36 antibody treatment that I observed between
cell lines in these studies.
Table 1. Genetic changes in PCa cell lines.
Cell Line

PTEN

p53

RB

LNCaP

Mutant

WT

WT

PC-3

Mutant

Mutant

WT

DU145

WT

Mutant

Mutant

To analyze the effect of TSP-1 on PEDF expression in vivo, I used TSP-1 KO
mouse prostate tissues. While the PEDF levels were slightly decreased in TSP-1 KO
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mice as compared to wildtype mice at 4 month of age, this was not statistically
significant and no difference were observed at 6 months of age. As only a few mice
were examined per group (3-4), analysis of additional tissues would be appropriate
to determine if an actual difference exists. As this TSP-1 KO is a developmental loss
model, it is possible that other PEDF regulating molecules are increasing PEDF
expression to compensate for the TSP-1 loss, and hence, no differences would be
observed in adult tissues.
TSP-1 binding to CD36 receptor in endothelial cells is associated with a wellestablished signaling cascade which includes several members of the family, src
kinase family, fyn, p38 MAPK and JNK (Figure 1). PCa cells are known to express
these signaling molecules [68]. Therefore, I analyzed if these mediators are
regulated by TSP-1 or neutralizing anti-CD36 antibody treatment in a subset of cell
lines PC-3 and DU145. The role of fyn in PCa is unclear. While one study reported
loss of fyn expression in PCa [107], another study showed overexpression [108]. My
data would support the former study, as no fyn was detected in untreated DU145 or
PC-3 cells. It has also been reported that fyn overexpression is linked to aberrant
PI3/ Akt pathway signaling leading to anti-apoptotic signals and other hallmarks of
cancer (reviewed in [109]). Since TSP-1 treatment increased fyn in my studies the
significance of this data in context of the currently published literature is unclear.
Since TSP-1 treatment induced fyn expression, while anti-CD36 antibody decreased
it, it would appear that fyn regulation is not mediated through a TSP-1 - CD36
pathway. However, this does lead to a new hypothesis that when CD36 receptor is
blocked, fyn expression, is downregulated which may also inhibit the PI3/Akt
pathway and lead to apoptosis in PCa cells. Future studies should be guided
towards testing this hypothesis.
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It is reported that both nuclear and total JNK expression is augmented in
human malignant prostate epithelium compared to benign tissue (reviewed in [110]).
My data would support this as JNK was expressed in DU145 untreated cells. JNK is
a mitogen-activated protein kinase known to have pro- and anti-apoptotic functions in
PCa, depending on the prostate cell line and treatment conditions used (reviewed in
[110]). In DU145 cells, TSP-1 treatment increased JNK expression at all doses.
Consistent with these data, Hubner et al. established that JNK deficiency in the
prostate epithelium may act to induce tumor development in a PTEN knockout model
[111]. Other studies suggest that JNK expression is tumor promoting. Kwon et al.
reported that chemical inhibition of JNK in DU145 cells reduced both cell migration
and VEGF expression [112]. It has also been reported that JNK promotes the
expression of some proteins responsible for cell invasion and tissue metastasis,
such as matrix metalloproteinases (MMPs) -2 and -9 and urokinase-type
plasminogen activator [112-114]. In my data, the increase in JNK was associated
with decreased proliferation which is consistent with a tumor suppressing activity.
It has been reported that both p38 and its active form p-p38 are
overexpressed in human cancerous prostatic epithelium [115-117]. My data would
support this as p38 was expressed in untreated PC-3 and DU145 cells. TSP-1
treatment did not change p38 expression in PC-3 cells, as compared to untreated
cells. In DU145 cells, p38 expression was elevated at higher doses (5, 10, 20 nM) of
TSP-1. Data obtained from blocking the CD36 receptor in DU145 cells shows that
p38 expression is diminished (2 μg/ml) or lost (5 μg/ml). In PC-3 cells blocking CD36
receptor shows that p38 expression is decreased at high dose of the antibody. p38
MAPK and its active form, p-p38, have been shown to be overexpressed in human
cancerous prostatic epithelium [110]. Huang et al. have shown that in PC-3 cells,
p38 MAPK activity is essential for TGF-β mediated activation of MMP-2, which aids
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in cell invasion [118]. Together, these data suggest that blocking the CD36 receptor
in PCa cells may be a novel anti-cancer therapeutic approach.
My data would also suggest that TSP-1 signaling is not acting through
inhibitory binding to CD36 since the opposite results the opposite results were
obtained with TSP-1 and anti-CD36 antibody treatments. Since all of these
molecules have established pro- as well as anti-apoptotic activity in PCa cells,
specific studies are needed to determine the roles of these signaling mediators in
PEDF expression and lipolytic activity.
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CONCLUSION
My hypothesis was that the TSP-1 - CD36 pathway of TSP-1 treatment or blocking
the CD36 regulated on PEDF expression in PCa cells and a normal cell prostate
epithelial cell line. As PEDF induces lipolysis in PCa cells, I assessed lipolytic
activity, cell proliferation and also possible signal mediators that could be involved in
TSP-1 - CD36 signaling. In PC-3 cells, I saw an induction in intracellular PEDF
expression when the CD36 receptor was blocked. Both TSP-1 treatment and
blocking the CD36 receptor in DU145 cells induced PEDF expression. Based on the
data collected, a summary model for both PC-3 and DU145 cells is presented
(Figure 24). RWPE-1 and LNCaP cells behaved similarly to PC-3 cells. My studies
also show that lipid metabolism is positively regulated by exogenous TSP-1 and by
blocking the CD36 receptor in PC-3 cells. In contrast, it is negatively regulated in
DU145 cells. Of the two pools of PEDF (intracellular and extracellular) intracellular
PEDF expression is believed to impact the lipolytic activity in a cell. In my studies, in
PC-3 LNCaP and RWPE-1 cells, both TSP-1 or anti-CD36 antibody treatment
induced intracellular PEDF and lipolytic activity, suggesting that PEDF may be
responsible for lipolytic activity. To test if lipolytic induction is dependent on PEDF
expression, future work should test TSP-1 and anti-CD36 antibody treatment in the
presence of an siRNA against PEDF. In contrast, in DU145 cells, while TSP-1
treatment or anti-CD36 antibody treatment induced intracellular PEDF expression,
lipolysis was inhibited. These data would suggest that, at least in DU145 cells, PEDF
does not induce lipolysis.
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Figure 24. Models of TSP-1 and CD36 receptor signaling in prostate cancer cells. Models
based on the data obtained for PC-3 (A) and DU145 (B) cells treated with TSP-1 and
neutralizing anti CD36 antibody are presented. TSP-1 treatment induced intracellular PEDF
expression in DU145 cells but not in PC-3 cells. Extracellular PEDF expression was inhibited in
DU145 but was enhanced in PC-3 cells. Blocking CD36 receptor also increased intracellular and
extracellular PEDF expression in both cell lines. Signaling mediators p38 and JNK were in both
cell lines with TSP-1 and neutralizing anti-CD36 antibody. Fyn expression was barely detectable
PC-3 cells.

To determine if signal mediators, fyn, p38 or JNK, were involved in TSP-1 or
CD36 receptor signaling in prostate cells, expression levels were analyzed.
Interestingly, both treatments altered levels of p38 MAPK and JNK in both PC-3 and
DU145 cells. However, the effects were the opposite for these treatments. TSP-1
increased the expression of these molecules while blocking the CD36 receptor
diminishes expression or had no effect. These data are also summarized in Figure
24. The effects of TSP-1 and anti-CD36 antibody treatment on PEDF expression,
lipolytic activity and signaling molecules in PC-3, LNCaP and RWPE-1 cells are
consistent with my hypothesis. However, the data obtained in DU145 cells is not. To
determine if these signaling molecules investigated here are necessary for PEDF
expression and/or lipolytic activity, future studies should block each of the signaling
kinases, using available chemical inhibitors, with TSP-1 or anti-CD36 antibody
treatment.
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